Cardiometabolic
Singapore wants healthcare AI that does not think like the West. Cardiometabolic care is its first real test
Singapore’s publicly funded SIMFONI programme will adapt foundation AI models using local clinical data, guidelines and workflows, beginning with cardiometabolic decision support in primary care and multimodal tools for eye disease. Localisation could make healthcare AI safer and more relevant. It could also automate local blind spots unless subgroup performance, accountability and clinical impact are…
EMA backs first oral obesity GLP-1 as pills push treatment towards mass-market adoption
As GLP-1 use expands, healthcare systems are confronting a new challenge: balancing obesity treatment with rising concerns about eating disorders and patient safety.
A new guideline is changing how health systems think about obesity, diabetes and heart disease
The next cardiometabolic battleground is ultra-processed food
ADA 2026 findings show diabetes drugs are no longer just chasing glucose
Physical activity continues to strengthen its case as a cross-disease prevention strategy
Can cortisol become the next target in type 2 diabetes?
Ozempic and Eye Health: Balancing Metabolic Benefits with Vision Risks
Europe’s Safe Hearts Plan Makes Prevention a Political Test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.